Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03261856 · ClinicalTrials.gov registry record
Clinical Utility of Breath Tests in GI
A clinical trial, sponsored by Augusta University.
- Completed
- Registry status
- 1,080
- Enrollment target
NCT03261856: Completed study, sponsored by Augusta University.
NCT03261856 is a clinical trial that has completed, run by Augusta University. The registered enrollment target is 1,080 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03261856 has completed, sponsored by Augusta University.
- COMPLETED
- Registry status
- 1,080 participants
- Enrollment target
Study Summary
Bloating, gas, pain and diarrhea are common complaints. Routine investigations are negative; these patients are labeled as IBS. In these patients, whether testing for carbohydrate malabsorption or small intestinal bacterial overgrowth (SIBO) is useful is unclear. Investigators aim to assess the prevalence of SIBO, fructose and lactose intolerance, the usefulness of breath tests, and predictive value of pre-test symptoms.
Primary Outcome
bacterial overgrowth which results in the inability to absorb nutrients
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,080 participants |
| Start Date | 2011-08-31 |
| Est. Completion | 2017-12-31 |
What the finished NCT03261856 record still lists
NCT03261856 is an observational study that tracks outcomes without assigning an intervention. Its 1,080 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03261856 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03261856 about?
NCT03261856 is a clinical study titled "Clinical Utility of Breath Tests in GI". Bloating, gas, pain and diarrhea are common complaints. Routine investigations are negative; these patients are labeled as IBS. In these patients, whether testing for carbohydrate malabsorption or small intestinal bacterial overgrowth (SIBO) is useful is unclear. Investigators aim to assess the prev...
What is the current status of trial NCT03261856?
This trial is currently completed. The enrollment target is 1,080 participants. The study started on 2011-08-31. Estimated completion is 2017-12-31.
Who is sponsoring clinical trial NCT03261856?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06074068 · 1,080 participants · NA
Father-Focused Intervention for Reducing Family Violence and Symptoms in Children
- NCT07213804 · 1,080 participants · Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
- NCT07084883 · 1,076 participants
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
- NCT06658808 · 1,075 participants · NA
Efficacy-Implementation Study for PC CARES in Rural Alaska
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI